Suggestions
Dirk Smeets
Transforming patient care with AI
Dirk Smeets is the Chief Technology Officer (CTO) at icometrix, a company focused on transforming patient care through artificial intelligence in medical imaging. He has held this position since September 2014 and has played a pivotal role in the company's strategic management, research and development, and product management, particularly for their MSmetrix and icobrain products.12
Background and Education
Dirk Smeets has a strong academic foundation with multiple degrees from Katholieke Universiteit Leuven, including a PhD in medical imaging. He has also participated in management programs at Vlerick Business School, enhancing his leadership skills within the healthcare technology sector.1
Professional Experience
- Chief Technology Officer (CTO) at icometrix since 2014, leading R&D and IT management.
- Previously served as Vice President of Clinical Applications and Chief Scientific Officer, contributing to the strategic direction of the company and overseeing various research projects.13
- Worked as an Expert Evaluator for the European Commission, assessing research proposals for funding.2
Contributions to Medical Imaging
Dirk has been instrumental in developing AI-driven solutions that assist clinicians in diagnosing and treating neurological diseases such as multiple sclerosis and Alzheimer's disease. His work emphasizes improving the accuracy and efficiency of MRI analysis through advanced machine learning techniques.56
Recognition
Smeets has received several awards for his contributions to medical imaging, including accolades for his research presentations at international conferences. His expertise is recognized both in academia and industry, making him a prominent figure in the field of biomedical engineering.14
Overall, Dirk Smeets combines technical expertise with leadership acumen to advance healthcare technology, aiming to enhance patient outcomes through innovative solutions.
Highlights
Exciting news today! After Aduhelm and Leqembi, Eli Lilly and Company's Kisunla (donanemab) is approved for the treatment of early symptomatic #Alzheimer's Disease. The phase III trial demonstrated it slowed cognitive and functional decline by up to 35% compared to placebo after 1.5 years.
Compared to Leqembi, Kisunla has a lower frequency of infusion (monthly instead of biweekly) and is the only medication with evidence to support stopping treatment when amyloid plaques are removed. At the downside, the rates of Amyloid related imaging abnormalities (#ARIA), the most common side effect, are higher.
As icometrix, we are committed to support the management of #ARIA with #AI, to reduce the possible negative impact of #ARIA. With synergies of innovative treatments and technology, we improve the lives of many patients.
